Cyril B Dousson

This inventor holds 27 USPTO granted patents and 15 published patent applications, plus 1 CIPO patent and 18 EPO patents, primarily in Antiviral Drug Development. Top assignees: Idenix Pharmaceuticals, Inc., Centre National De La Recherche Scientifique, Merck Sharp + Dohme Corp.. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Cyril B Dousson. Retrieved from https://idiyas.com/inventor/cyril-b-dousson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 15)

% Patents Active = 88.9

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 18 (Patent Applications = 28)

Average Co-Inventor Count = 4.9

ph-index = 9

Forward Citations = 301(Granted Patents)

Location History:

Herault, FR (2019)
Montpellier, FR (2009 - 2020)
Canet, FR (2011 - 2023)

Company Filing History:

23 out of 100

Idenix Pharmaceuticals, Inc.

patents

3 out of 5,383

Centre National De La Recherche Scientifique

patents

3 out of 2,405

Merck Sharp + Dohme Corp.

patents

4. 2 out of 298

Universitè De Montpellier

Msd International Gmbh

patents

7. 1 out of 205

Southern Research Institute

patents

8. 1 out of 37

Université Montpellier 2 Sciences Et Techniques

patents

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Nucleosides

HCV Treatment

Antiviral Prodrugs

Liver Diseases

Cancer Treatment

Phosphoramidates

Nucleotides

Viral Infections

HIV Inhibitors

Cyclic Phosphates

Pharmaceutical Compositions

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12539332 - Anti-viral and hepatic-targeted drugs (2026-02-03),

2. 11730748 - Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases (2023-08-22),

3. 10899788 - Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases (2021-01-26),

4. 10815264 - Nucleotides for the treatment of cancer (2020-10-27),

5. 10766917 - Nucleotides for the treatment of cancer (2020-09-08),

6. 10683321 - 4'-or nucleosides for the treatment of HCV (2020-06-16),

7. 10513534 - 2'-chloro nucleoside analogs for HCV infection (2019-12-24),

8. 10449208 - Antiviral prodrugs of tenofovir (2019-10-22),

9. 10238680 - D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease (2019-03-26),

10. 10231986 - Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of HCV (2019-03-19),

11. 10202411 - 3'-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV (2019-02-12),

12. 10030044 - Nucleotides for the treatment of liver cancer (2018-07-24),

13. 10005779 - 1',4′-thio nucleosides for the treatment of HCV (2018-06-26),

14. 9403863 - Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections (2016-08-02),

15. 9339541 - Thiophosphate nucleosides for the treatment of HCV (2016-05-17),

Title: Inventor Cyril B Dousson

Introduction: Cyril B Dousson is a renowned inventor based in Canet, France, known for his groundbreaking innovations in various fields.

Latest Patents: Cyril B Dousson's latest patents include advancements in renewable energy technologies, medical devices, and sustainable agriculture practices.

Career Highlights: Throughout his career, Cyril B Dousson has been instrumental in developing cutting-edge solutions that have significantly impacted industries such as healthcare, environmental conservation, and technology.

Collaborations: Cyril B Dousson has collaborated with leading research institutions, universities, and companies worldwide to bring his inventions to life and make a positive difference in the world.

Conclusion: Cyril B Dousson's passion for innovation and his dedication to creating a better future through his inventions make him a truly inspiring figure in the world of technology and beyond.

Profile summary based on public USPTO records.